IL6 and pulmonary arterial hypertension: Nonetheless, there was a signal that the treatment had higher efficacy in patients with connective tissue disease (CTD)-associated PAH, where higher levels of IL6 have been described compared to other PAH etiologies, emphasizing the heterogeneity of the disease and the importance of differentiating patients within the PAH umbrella diagnosis [172,173].